|1.||He, Yuxian: 4 articles (10/2014 - 04/2008)|
|2.||Jiang, Shibo: 3 articles (02/2011 - 04/2008)|
|3.||Wang, Meitian: 2 articles (10/2014 - 03/2013)|
|4.||Zhang, Meng: 2 articles (10/2014 - 03/2013)|
|5.||Qiu, Zonglin: 2 articles (10/2014 - 03/2013)|
|6.||Sun, Jianping: 2 articles (10/2014 - 03/2013)|
|7.||Yao, Xue: 2 articles (10/2014 - 03/2013)|
|8.||Chong, Huihui: 2 articles (10/2014 - 03/2013)|
|9.||Cui, Sheng: 2 articles (10/2014 - 03/2013)|
|10.||Zhang, Linqi: 2 articles (02/2011 - 04/2008)|
10/01/2014 - "Compared with sifuvirtide, MT-SFT exhibited a significant improvement in the ability to bind to the N-terminal heptad repeat, to block the formation of the six helix bundle and to inhibit HIV-1 Env-mediated cell fusion, viral entry and infection. "
04/25/2008 - "We demonstrated that sifuvirtide inhibited HIV-1-mediated cell-cell fusion in a dose-dependent manner and exhibited high potency against infections by a wide range of primary and laboratory-adapted HIV-1 isolates from multiple genotypes with R5 or X4 phenotypes. "
03/01/2013 - "Amazingly, MT-SC22EK inhibited HIV-1-mediated cell fusion and infection at a level comparable to C34, T1249, SC29EK, and sifuvirtide, and it was highly active against diverse HIV-1 subtypes and variants, including those T20 (enfuvirtide) and SC29EK-resistant viruses. "
02/04/2011 - "Sifuvirtide, a novel fusion inhibitor against human immunodeficiency virus type I (HIV-1), which is more potent than enfuvirtide (T20) in cell culture, is currently under clinical investigation for the treatment of HIV-1 infection. "
03/13/2009 - "Here, we found that a combination of enfuvirtide and sifuvirtide resulted in potent synergism in inhibiting HIV-1-mediated cell-cell fusion and infection by X4 and R5 as well as enfuvirtide-resistant HIV-1 strains. "
|2.||Acquired Immunodeficiency Syndrome (AIDS)